There was a tour de table of Member States, with many stressing that these were only initial estimates
at this point, and that there were many variables (e.g. the times at which different vaccines became
available, the durability of any immune response). Member State estimates varied from 20% to 100%
of their population. A rough summary is provided in the table below:
Member State
Austria (tbc)
Belgium
Bulgaria
Croatia (tbc)
Cyprus (tbc)
Czech Republic (tbc)
Denmark
Estonia
Finland (tbc)
France
Germany (tbc - assumption)
Greece (tbc)
Hungary (tbc)
Ireland (tbc)
Italy
Latvia (tbc)
Lithuania
Luxembourg (tbc)
Malta
Netherlands
Poland (tbc)
Portugal
Romania (tbc)
Slovakia (tbc)
Slovenia
Spain
Sweden (tbc)
ESTIMATED TOTAL (status of 3rd July 2020)
Update on contacts with companies
The Commission gave an overview of the ongoing negotiations with Johnson & Johnson, Sanofi, and
Moderna. There had been introductory calls with a number of companies this week (
). More detailed information was expected from at least a
couple of the previous contacts in the course of the next week. The Commission would work with
those companies to get enough information to enable the Steering Board to make an informed decision
about whether or not to open negotiations with them.
In response to a request from Member States, it was agreed to have an agenda point in the near future
giving an overview of the most promising vaccine candidates.
A dedicated session on liability would be arranged.